| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
353,480,000 |
| Market
Cap: |
335.56(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.75 - $7.94 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Bionano Genomics is a global genomics company focused on elevating the health and wellness of all people. Co. provides optical genome mapping, or OGM, for genome analysis and provide a suite of genome analysis solutions designed to enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. Co. provides OGM and software solutions for applications across applied, translational and clinical research and it provides diagnostic services to physicians focusing in medical management for individuals with genetic conditions such as pediatric neurodevelopmental disorders, including autism spectrum disorders. Co. market and sells the Saphyr® system.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
130,789 |
140,789 |
| Total Buy Value |
$0 |
$0 |
$93,054 |
$109,054 |
| Total People Bought |
0 |
0 |
3 |
4 |
| Total Buy Transactions |
0 |
0 |
3 |
4 |
| Total Shares Sold |
0 |
0 |
0 |
20,000 |
| Total Sell Value |
$0 |
$0 |
$0 |
$72,402 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Holmlin R. Erik |
PRESIDENT AND CEO |
• • – |
2024-02-15 |
4 |
D |
$1.27 |
$3,903 |
D/D |
(3,073) |
77,663 |
|
- |
|
| Dixon Jonathan V. |
GENERAL COUNSEL |
• – – |
2024-02-15 |
4 |
D |
$1.27 |
$511 |
D/D |
(402) |
3,525 |
|
- |
|
| Chaubey Alka |
CHIEF MEDICAL OFFICER |
• – – |
2024-02-15 |
4 |
D |
$1.27 |
$1,373 |
D/D |
(1,081) |
31,487 |
|
- |
|
| Borodkin Mark |
CHIEF OPERATING OFFICER |
• – – |
2024-02-15 |
4 |
D |
$1.27 |
$1,561 |
D/D |
(1,229) |
48,644 |
|
- |
|
| Borodkin Mark |
Chief Operating Officer |
• – – |
2023-09-18 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
317,842 |
|
- |
|
| Chaubey Alka |
Chief Medical Officer |
• – – |
2023-09-18 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
144,794 |
|
- |
|
| Mamuszka Hannah |
Director |
– • – |
2023-06-13 |
4 |
B |
$0.76 |
$50,000 |
D/D |
65,789 |
65,789 |
2.39 |
-79% |
|
| Holmlin R. Erik |
President and CEO |
• • – |
2023-05-16 |
4 |
B |
$0.64 |
$9,639 |
D/D |
15,000 |
806,474 |
2.81 |
-55% |
|
| Stewart Christopher P. |
Chief Financial Officer |
• – – |
2023-05-12 |
4 |
B |
$0.67 |
$33,415 |
D/D |
50,000 |
281,373 |
2.74 |
-55% |
|
| Borodkin Mark |
Chief Operating Officer |
• – – |
2023-05-12 |
4 |
D |
$0.66 |
$27,387 |
D/D |
(41,496) |
297,842 |
|
- |
|
| Holmlin R. Erik |
President and CEO |
• • – |
2023-05-12 |
4 |
D |
$0.66 |
$33,093 |
D/D |
(50,141) |
791,474 |
|
- |
|
| Dixon Jonathan V. |
General CounselOfficer |
• – – |
2023-02-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
39,270 |
|
-53% |
|
| Chaubey Alka |
Chief Medical Officer |
• – – |
2023-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
120,000 |
124,794 |
|
- |
|
| Stewart Christopher P. |
Chief Financial Officer |
• – – |
2023-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
105,000 |
231,373 |
|
- |
|
| Borodkin Mark |
Chief Operating Officer |
• – – |
2023-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
120,000 |
339,338 |
|
- |
|
| Holmlin R. Erik |
President and CEO |
• • – |
2023-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
300,000 |
841,615 |
|
- |
|
| Linney Yvonne |
Director |
– • – |
2022-08-15 |
4 |
S |
$3.62 |
$72,402 |
D/D |
(20,000) |
0 |
|
61% |
|
| Linney Yvonne |
Director |
– • – |
2022-08-15 |
4 |
OE |
$0.38 |
$7,600 |
D/D |
20,000 |
20,000 |
|
- |
|
| Barker David L |
Director |
– • – |
2022-07-07 |
4 |
OE |
$0.51 |
$22,680 |
D/D |
44,470 |
58,364 |
|
- |
|
| Barker David L |
Director |
– • – |
2022-05-16 |
4 |
B |
$1.60 |
$16,000 |
D/D |
10,000 |
13,894 |
2.39 |
15% |
|
| Stewart Christopher P. |
Chief Financial Officer |
• – – |
2022-05-13 |
4 |
OE |
$0.56 |
$33,600 |
D/D |
60,000 |
121,579 |
|
- |
|
| Borodkin Mark |
Chief Operating Officer |
• – – |
2022-05-12 |
4 |
D |
$1.41 |
$58,509 |
D/D |
(41,496) |
216,669 |
|
- |
|
| Holmlin R. Erik |
President and CEO |
• • – |
2022-05-12 |
4 |
D |
$1.41 |
$70,699 |
D/D |
(50,141) |
538,556 |
|
- |
|
| Shams Soheil |
Chief Informatics Officer |
• – – |
2021-10-18 |
4 |
A |
$0.00 |
$0 |
D/D |
5,325,378 |
5,325,378 |
|
- |
|
| Stewart Christopher P. |
Chief Financial Officer |
• – – |
2021-05-26 |
4 |
OE |
$0.56 |
$14,000 |
D/D |
25,000 |
33,000 |
|
- |
|
42 Records found
|
|
Page 1 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.01 (0.96%) 
